• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

UK Startup Flow Raises $1.5M for Brain Stimulation Headset, Therapy App

by Fred Pennic 07/26/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Flow Launches Medical-Grade Headset, Therapy App for Depression

Flow, a London-based medical device startup using a brain stimulation headset and therapy app to treat depression has raised $1.5 million in seed funding led by Khosla Ventures. In Europe, Flow has been approved as a Class II medical device intended for use as a treatment for depression – and is the first approved treatment of its kind in Europe available to buy and use at home. The investment will be used to support Flow’s European rollout, introduce Flow to healthcare clinics, and fund clinical studies.

Flow Background

Based in Sweden, Flow was developed by clinical psychologist Daniel Mansson and neuroscientist Erik Rehn, together with a team of prominent researchers in the field of psychiatry and brain stimulation. Flow is starting talks with the NHS to have its brain stimulation headset available on prescription. In 2019, Flow will also be working with the U.S. Food and Drug Administration (FDA) to seek regulatory clearance in the U.S.

Impact of Depression in the UK

According to WHO, depression is the leading cause of disability worldwide affecting over 300 million people – and effective, non-pharmacological alternative treatments cannot come soon enough. Meanwhile, in the UK, nearly one in four adults are affected by a mental illness. Suicide is the most common cause of death for men aged 20-49 years in England and Wales. The economic costs of mental illness in England is estimated at £105.2 billion annually. And one in three work sickness notes handed out by GPs are for mental health reasons, including depression.

People diagnosed with depression often have lower neural activity in their left frontal lobe, the part of the brain controlling important cognitive skills including emotional expression. The Flow headset uses transcranial direct current stimulation (tDCS), a form of neurostimulation that delivers constant, low direct current via electrodes on the head to stimulate and rebalance neural activity in this area.  

The brain stimulation headset is used in combination with a therapy app. This educates users with videos about depression and advice on how to reduce symptoms using the latest expert knowledge from the fields of sleep, nutrition, fitness, and meditation. 

How It Works

Flow Launches Medical-Grade Headset, Therapy App for Depression

Treatment typically lasts for 30 minutes per session, with 18 sessions over 6 weeks. Continued treatment is then possible for 1-2 sessions per week. During brain stimulation, users engage with a virtual therapist, via an app. This features videos and advice about depression, and how to reduce symptoms, using recent expert knowledge from the fields of sleep, nutrition, fitness, and meditation.

“We’re increasing treatment choice and empowering people to self-manage their symptoms at home with an effective, personalized and non-pharmacological alternative. This has the potential to improve the standard of care, and reduce global healthcare costs. The Khosla Ventures investment will support the next stage of our journey as we cement our position as European leaders of brain stimulation treatment for depression,” said Daniel Mansson, Clinical Psychologist and Co-Founder of Flow.  

Headset/App Availability

The Flow headset retails at £399 and is available for purchase here. The Flow virtual therapy app, available on iOS, is free and can be downloaded here.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Depression, FDA, Flow Neuroscience, global healthcare, Khosla Ventures, Medical Device, Medical Grade Wearable, Medical Grade Wearables, medication, Mental Health, Mental Illness, NHS

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |